The statement's timing does make me think they know 3rd Quarter earnings are scary. I'm guessing at least a $50 million loss, or more. The first thing a new board might want to do is find a new president who understands how to promote and put some energy behind a great product. Feels like the company's currently run by a former Merck middle-level management guy with expertise at negotiating contracts in Europe but no understanding of how to fight against forces trying to undermine the company: generics, fish oil supplements and Lovaza.
This should be the quarter when sales are starting in England and elsewhere since five countries were to begin sales by the end of this year. Yet, the company's last news releases were six weeks ago.
rosemount, the prospect of dilution became very real during the last earnings release. KM said this quarter will be worse. (Can be fixed if they cut back buying API). This may save it going sub $1. Considering how badly the overall market is right now, a sale at even $10 would be great with so many other deals out there. 200 companies in the S&P 500 hit 52 week lows last week. Of course I would love more than $10, but we have to be realistic considering where the EU is right now.
News 
Market Data 
Discover 
